Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells

(2011) Yoshihiro Inamoto et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation

(2011) Y. Inamoto et al.   BLOOD

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

(2011) M. E. D. Flowers et al.   BLOOD

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

(2011) J. E. Cortes et al.   BLOOD

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

(2011) S M Luger et al.   BONE MARROW TRANSPLANTATION

Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

(2011) Claire Roddie et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

(2011) R. Ram et al.   HAEMATOLOGICA

Impact of Recipient Statin Treatment on Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

(2010) Marcello Rotta et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Use of Matched Unrelated Donors Compared with Matched Related Donors Is Associated with Lower Relapse and Superior Progression-Free Survival after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation

(2010) Vincent T. Ho et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive Non-Hodgkin Lymphomas

(2010) Erica D. Warlick et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia

(2010) J. Choi et al.   BLOOD

Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies

(2010) Didier Blaise et al.   EXPERIMENTAL HEMATOLOGY

The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation

(2010) S Thepot et al.   LEUKEMIA

What Is the Role for Donor Natural Killer Cells after Nonmyeloablative Conditioning?

(2009) Frédéric Baron et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose

(2009) M. A. Pulsipher et al.   BLOOD

Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation

(2009) M. Rotta et al.   BLOOD

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation

(2008) O. Ringden et al.   BLOOD

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

(2008) Mauricette Michallet et al.   EXPERIMENTAL HEMATOLOGY